The Pags Group
VC Fund
The Pags Group is a VC fund focused on Biotechnology and Pharmaceutical. The Pags Group operates as the family office of Stephen Pagliuca.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries The Pags Group invests in
Stages The Pags Group invests in
Countries The Pags Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Seed
- $2.3M–$38M
- Series A
- $80M–$250M
- Series B
- $15M–$70M
Investment Focus
Industry
- Biotechnology 5 (28%)
- Pharmaceutical 4 (22%)
- Medical 3 (17%)
- Health Care 3 (17%)
- Consumer 2 (11%)
Stage
- Seed 5 (28%)
- Series B 3 (17%)
- Series A 2 (11%)
- Series D 2 (11%)
- Series C 1 (6%)
Country
- United States 12 (67%)
- Singapore 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dr. Mey Boukenna
president
|
president | Total investments: 1 | Find email | |
Stephen Pagliuca
Founder
|
Founder | Total investments: 24 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Gameto
|
Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to changethat.Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Gameto's first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno. | $44M / Series C / Aug 12, 2025 | |
Liquid AI
|
Building AGI, AI as Service, Generative AI | $250M / Series A / Dec 13, 2024 | |
Ladder
|
Ladder is a strength training app that provides a workout plan, every single day. Fitness-seekers can access a complete strength training program on their phone, learn from an expert coach, and engage with a community that shares a passion for fitness. The company is based in Austin, Texas. | $90M / Debt Financing / Nov 20, 2024 | |
|
Ladder
|
Ladder is a strength training app that provides a workout plan, every single day. Fitness-seekers can access a complete strength training program on their phone, learn from an expert coach, and engage with a community that shares a passion for fitness. The company is based in Austin, Texas. | $15M / Series B / Nov 19, 2024 | |
Seismic Therapeutic
|
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements ofbiologics drug discovery – structural biology, protein engineering, and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to address adaptive immune system dysregulation to treat autoimmune diseases. | $25M / Series B / Sep 12, 2024 | |
Milu Health
|
Milu Health uses EHR, claims, and pricing data to find healthcare cost-saving opportunities. | $4.8M / Seed / Mar 11, 2024 | |
Artemis
|
Powered by AI, Mona Lee is the fastest, most efficient way for homeowners to go solar. Through a direct-to-consumer approach, Mona Lee’s AI-powered self-serve platform transforms the solar buying experience by eliminating non-stop solicitation calls, lengthy design and evaluation processes, and back-and-forth price negotiations that can take up toweeks. With Mona Lee, customers go from quote to scheduling their installation in minutes. Feel free to visit our website to read customer testimonials and Mona Lee solar reviews.Mona Lee was founded by a group of serial entrepreneurs with decades of experience in clean energy. The company is headquartered in Boston, MA and is proud to serve homeowners nationwide. | $3.3M / Seed / Mar 08, 2024 | |
Tectonic Therapeutic
|
Tectonic is a privately held biotechnology company that aims to transform the discovery of novel GPCR-targeted drugs and unlock the therapeutic utility the most challenging receptors in the class. Tectonic’s founders are at the forefront of scientific research in biochemistry and molecular pharmacology with an extensive track record ofentrepreneurial achievement. | $130.7M / Post-IPO Equity / Jan 30, 2024 | |
Ratio Therapeutics
|
Ratio Therapeutics develops radiotherapeutics for the treatment of cancers. They engaged in research and development platforms, trillium and macropa, enable the imaging, discovery, and advancement of radiopharmaceuticals. It enables doctors to detect a wide range of epithelial-derived cancers, such as breast, pancreatic, lung, colon cancers, andmore. | $50M / Series B / Jan 17, 2024 | |
|
Liquid AI
|
Building AGI, AI as Service, Generative AI | $37.5M / Seed / Dec 01, 2023 | |
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does The Pags Group invest in?
The Pags Group invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Seed and Series B stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is The Pags Group's check size?
The Pags Group typically joins rounds of $2.3M–$38M at Seed, $80M–$250M at Series A and $15M–$70M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds The Pags Group participates in.
How do I contact The Pags Group?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at The Pags Group?
The team at The Pags Group includes Dr. Mey Boukenna (president) and Stephen Pagliuca (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
